Click Here to Register »

2017 Exhibitors

Personalis

2017 Supporting Partners

CRI
SITC

2017 Media Partners

BioPharma Dive
Clinical Leader
Life Science Leader
MNT
Pharmaceutical Online
Pharmalicensing
pharmaphorum
SciDoc Publishers
Technology Networks

Novel Trial Designs, Business Development & Scientific Data for Immuno-Oncology Combinations

2017 Featured Speakers

AxelHoos_colorAxel Hoos, MD, PhD
GSK
Patrick_Hwu_colorPatrick Hwu, MD
MD Anderson
Ian McCafferyIan McCaffrey, PhD
Corvus Pharmaceuticals
Julie Hambleton, MD
BMS
Stanley Frankel, MD
Celgene
Roy BaynesRoy Baynes, MD, PhD
Merck
Lisa Butterfield, PhD
University of Pittsburgh
Ramy Ibrahim, MD
Parker Institute 

Overview

The Conference Forum is delighted to present the 2nd annual Rational Combinations 360°, the only event addressing business aspects, novel clinical trial designs and scientific developments for combination immunotherapies.

With promising cancer immunotherapies in the clinic and an encouraging pipeline of new targets being developed, additional discoveries are now under way to determine the most effective rational combinations that are personalized for individual patients and for specific tumor types. Increased emphasis on prioritizing combinations will be crucial for decision-making. Both small and large companies are now racing to bring game-changing combination therapies to the market. As a result, novel therapies and innovative trial designs are creating increased momentum for investment/business development opportunities.

Designed by lead advisors Dr Axel Hoos (GSK), Dr Patrick Hwu (MD Anderson) and Dr Ian McCaffery (Corvus Pharmaceuticals), Rational Combinations 360° provides the most up-to-date progress on combination developments from business aspects, clinical advancements and scientific data that will help prioritize the best cancer treatments for individual patients and tumor types.

The Rational Combinations 360° event delved into key areas including:

  • Derisking of Combination Immunotherapies
  • Clinical Combination Immunotherapies
  • Immuno Resistance – Drivers for Combination Therapy
  • Novel Technologies and Emerging Biomarkers
  • Clinical Manifestations of Immunological Toxicities
  • Business Aspects for Combination Immunotherapy

If you would like to participate in the 2nd annual Rational Combinations 360° program, contact us at service@tcfllc.org.

Thanks and we look forward to seeing you in June.

Sincerely,

Kate-BW-2

 

 

Kate Woda
Conference Director

Valerie Bowling New

 

 

Valerie Bowling
Executive Director

Meredith Sands B&W-46

 

 

Meredith Sands
Executive Director, Business Development

Elizabeth Bard B&W-47

 

 

Elizabeth Bard
Business Development Manager

geeta-new-bw

 

 

Geeta Bachani
Business Development Manager

Nancy-BW-2

 

 

Nancy Belis
Conference Planner & Logistics


Testimonials

  • "I absolutely enjoyed the meeting! It was great getting both academia and industry together to discuss how we move forward."

    - Robert Andtbacka, Huntsman Cancer Institute

  • "Thanks so much for putting on a great conference. It was very informative and I was excited to be a part of it. I am looking forward to the next one!"

    - Amanda Bruno, GSK

  • "It was a great conference. I learned a lot and enjoyed the diversity of speakers"

    - Julia Keith, RA Capital

  • "It was great meeting. I really enjoyed the conference and my interactions with several of the participants."

    - Jeffrey Wallin, Genentech